2025-06-05-Jefferies-赛诺菲治疗公司（SRPT）_FDA新平台技术指定授予LGMD基因疗法_10页_965kb

Sarepta Therapeutics (SRPT) Equity Research Summary

Overview

Sarepta Therapeutics is a commercial-stage biopharmaceutical company developing RNA-targeted therapeutics and gene therapies for rare diseases, such as Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMD). The company, with a market capitalization of $3.8B and ticker SRPT, has received a BUY rating from Jefferies Research, driven by its innovative gene therapy platform and recent regulatory advancements. The price target is $125.00, reflecting a potential 216% upside from current trading at $39.54.

Key Recommendations and Price Target

• Rating: BUY
• Price Target: $125.00 (+216% upside)
• Peak Sales Potential: The market may value the DMD franchise, including Elevidys, at $1.3B+ with a 3x revenue multiple, supporting the price target. This valuation is underpinned by the Platform Technology Designation (PTD) and positive FDA engagement.

Market and Stock Performance

• The stock remains pressured due to a fatal acute liver failure (ALF) incident with Elevidys in DMD patients. This event may cause quarterly sales to decline (potentially 20% Q/Q), but KOLs view it as an unusual rather than systemic issue. Recovery may occur in Q3 2025 after the impact subsides.

Pipeline and Therapeutic Developments

• Gene Therapies: Sarepta is advancing LGMD programs using its AAVrh74 vector, with SRP-9003 (for LGMD 2E/R4) benefiting from a PTD from the FDA, which could streamline BLA filings in H2 2025. Ongoing Phase III trials are expected to provide key data mid-year. Other programs, such as SRP-9004 and SRP-9005, are in early development stages.
• RNAi Therapies: The pipeline includes subcutaneous and intravenous RNAi candidates targeting diseases like facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1 (DM1), with potential launches in 2028 and 2029.
• Existing Products: Elevidys, Exondys 51, Vyondys 53, and Amondys 45 are approved commercial products in DMD, though recent safety concerns linger.

Regulatory and Operational Updates

• FDA Support: The FDA has granted PTD for Sarepta's AAVrh74 vector, facilitating quicker regulatory reviews and leveraging historical data from Elevidys, which has been administered to over 800 patients worldwide.
• Expansion Potential: Pipeline designations may enable the company to apply the same technology to future therapies, reducing development timelines for rare disease treatments.

Investment Risks

• The DCF-based valuation incorporates risks, including clinical trial failures, regulatory hurdles, competition, biosimilars, and reimbursement challenges. The company's focus on ultra-rare diseases may limit trial enrollment and manufacturing scalability.

Analyst Certifications and Disclosure

Analysts confirm the views in this report are based on a substantive analysis, with no compensation tied to recommendations. Jefferies has disclosed potential conflicts through investment banking ties with clients like Arrowhead Pharmaceuticals and Roche, emphasizing the need to consider these in investment decisions.